Back to Trials
NCT07599904Recruiting

REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)

Medtronic Neurovascular Clinical Affairs

Start Date

7/13/2026

Completion Date

7/1/2031

Summary

Post-Market Registry

Detailed Description

An observational, prospective, multi-center, single-arm registry to provide continuing evaluation of safety and effectiveness of Medtronic Neurovascular commercially available products used in the treatment of acute ischemic stroke.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: 1. Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements. 2. Participant is treated or intended to be treated with a commercially available Medtronic Neurovascular device\* during treatment for acute ischemic stroke. 3. Participant is 18 years of age or older. Exclusion Criteria: 1. Participant who may be unable to complete follow-up within the registry. 2. Participant of child-bearing potential who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study. 3. Participant is currently enrolled in, or plans to enroll in, any concurrent drug/device study that may confound the study results based on Principal Investigator's discretion.

Interventions

DEVICE

Mechanical Thrombectomy

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Acute Ischemic Stroke

Locations

McLaren Flint Hospital

Flint, Michigan 48532

United States

Buffalo General Medical Center

Buffalo, New York 14203

United States

University of Texas Health Science Center at Houston

Houston, Texas 77030

United States